参考文献/References:
[1]张静,张蓓蓓,蔡辉.系统性红斑狼疮发病机制和生物学标志物的研究进展[J].现代医学,2017,45(6):887-890.[2]周立偲,田浤,高向东,等.生物技术药物治疗系统性红斑狼疮的研究进展[J].药学与临床研究,2014(3):251-256.[3]姜桐桐,史铁英,王林.基于关键词共现的健康坚韧性国外研究分析[J].中国健康教育,2017,33(12):1121-1125.[4]Perez-Sanchez C,Barbarroja N,Messineo S,et al.Gene profiling reveals specific molecular pathways in the pathogenesis of atherosclerosis and cardiovascular disease in antiphospholipid syndrome, systemic lupus erythematosus and antiphospholipid syndrome with lupus[J].Ann Rheum Dis,2015,74(7):1441-1449.[5]Cuadrado MJ,Bertolaccini ML,Seed PT,et al.Low-dose aspirin vs low-dose aspirin plus low-intensity warfarin in thromboprophylaxis:a prospective,multicentre,randomized,open, controlled trial in patients positive for antiphospholipid antibodies(ALIWAPAS)[J].Rheumatology (Oxford),2014,53(2):275-284.[6]Sciascia S,Cuadrado MJ,Sanna G,et al.Thrombotic risk assessment in systemic lupus erythematosus:validation of the global antiphospholipid syndrome score in a prospective cohort[J].Arthritis Care Res(Hoboken),2014,66(12):1915-1920.[7]Sciascia S,Sanna G,Murru V,et al.Validation of a commercially available kit to detect anti-phosphatidylserine/prothrombin antibodies in a cohort of systemic lupus erythematosus patients[J].Thromb Res,2014,133(3):451-454.[8]Bertolaccini ML,Sciascia S,Sanna G,et al.Antiphosphatidylserine/prothrombin antibodies in systemic lupus erythematosus[J].J Rheumatol,2013,40(9):1620.[9]Matta BN,Uthman I,Taher AT,et al.The current standing of diagnosis of antiphospholipid syndrome associated with systemic lupus erythematosus[J].Expert Rev Clin Immunol,2013,9(7):659-668.[10]Nayfe R,Uthman I,Aoun J,et al.Seronegative antiphospholipid syndrome[J].Rheumatology (Oxford),2013,52(8):1358-1367.[11]Costedoat-Chalumeau N,Amoura Z,Hulot JS,et al.Very low blood hydroxychloroquine concentration as an objective marker of poor adherence to treatment of systemic lupus erythematosus[J].Annals of the rheumatic diseases,2007,66(6):821-824.[12]Costedoat-Chalumeau N,Amoura Z,Hulot JS,et al.Low blood concentration of hydroxychloroquine is a marker for and predictor of disease exacerbations in patients with systemic lupus erythematosus[J].Arthritis and rheumatism,2006,54(10):3284-3290.[13]Costedoat-Chalumeau N,Le Guern V,Piette J C.Routine Hydroxychloroquine Blood Concentration Measurement in Systemic Lupus Erythematosus Reaches Adulthood[J].J Rheumatol,2015,42(11):1997-1999.[14]Costedoat-Chalumeau N,Galicier L,Aumaitre O,et al.Hydroxychloroquine in systemic lupus erythematosus: results of a French multicentre controlled trial(PLUS Study)[J].Ann Rheum Dis,2013,72(11):1786-1792.[15]Costedoat-Chalumeau N,Hulot JS,Amoura Z,et al.Heart conduction disorders related to antimalarials toxicity:an analysis of electrocardiograms in 85 patients treated with hydroxychloroquine for connective tissue diseases[J].Rheumatology(Oxford),2007,46(5):808-810.[16]Costedoat-Chalumeau N,Amoura Z,Le Thi Huong D,et al.Pleading to maintain hydroxychloroquine throughout Lupus pregnancies[J].Rev Med Interne,2005,26(6):467-469.[17]Costedoat-Chalumeau N,Amoura Z,Huong DL,et al.Safety of hydroxychloroquine in pregnant patients with connective tissue diseases.Review of the literature[J].Autoimmunity Reviews,2005,4(2):111-115.[18]Costedoat-Chalumeau N,Amoura Z,Duhaut P,et al.Safety of hydroxychloroquine in pregnant patients with connective tissue diseases:a study of one hundred thirty-three cases compared with a control group[J].Arthritis and Rheumatism,2003,48(11):3207-3211.[19]Steinberg AD,Gourley M.Cyclophosphamide in lupus nephritis[J].The Journal of Rheumatology,1995,22(10):1812-1815.[20]Illei GG,Takada K,Parkin D,et al.Renal flares are common in patients with severe proliferative lupus nephritis treated with pulse immunosuppressive therapy:long-term followup of a cohort of 145 patients participating in randomized controlled studies[J].Arthritis and Rheumatism,2002,46(4):995-1002.[21]Illei GG,Austin HA,Crane M,et al.Combination therapy with pulse cyclophosphamide plus pulse methylprednisolone improves long-term renal outcome without adding toxicity in patients with lupus nephritis[J].Annals of Internal Medicine,2001,135(4):248-257.[22]Isenberg DA.Treating patients with lupus with B-cell depletion[J].Lupus,2008,17(5):400-404.[23]Cambridge G,Isenberg DA,Edwards JC,et al.B cell depletion therapy in systemic lupus erythematosus:relationships among serum B lymphocyte stimulator levels,autoantibody profile and clinical response[J].Ann Rheum Dis,2008,67(7):1011-1016.[24]Ioannou Y,Lambrianides A,Cambridge G,et al.B cell depletion therapy for patients with systemic lupus erythematosus results in a significant drop in anticardiolipin antibody titres[J].Annals of the Rheumatic Diseases,2008,67(3):425-426.[25]Ng KP,Cambridge G,Leandro MJ,et al.B cell depletion therapy in systemic lupus erythematosus: long-term follow-up and predictors of response[J].Annals of the Rheumatic Diseases,2007,66(9):1259-1262.[26]Cambridge G,Leandro MJ,Teodorescu M,et al.B cell depletion therapy in systemic lupus erythematosus:effect on autoantibody and antimicrobial antibody profiles[J].Arthritis and Rheumatism,2006,54(11):3612-3622.[27]Ng KP,Leandro MJ,Edwards JC,et al.Repeated B cell depletion in treatment of refractory systemic lupus erythematosus[J].Annals of the Rheumatic Diseases,2006,65(7):942-945.[28]Leandro MJ,Cambridge G,Edwards JC,et al.B-cell depletion in the treatment of patients with systemic lupus erythematosus:a longitudinal analysis of 24 patients[J].Rheumatology(Oxford, England),2005,44(12):1542-1545.[29]Furtado J,Isenberg DA.B cell elimination in systemic lupus erythematosus[J].Clin Immunol,2013,146(2):90-103.[30]Taher TE,Muhammad HA,Bariller E,et al.B-lymphocyte signalling abnormalities and lupus immunopathology[J].Int Rev Immunol,2013,32(4):428-444.[31]Taher TE,Muhammad HA,Rahim A,et al.Aberrant B-lymphocyte responses in lupus:inherent or induced and potential therapeutic targets[J].European Journal of Clinical Investigation,2013,43(8):866-880.[32]Bosma A,Abdel-Gadir A,Isenberg DA,et al.Lipid-antigen presentation by CD1d(+)B cells is essential for the maintenance of invariant natural killer T cells[J].Immunity,2012,36(3):477-490.[33]Ezeonyeji AN,Isenberg DA.Early treatment with rituximab in newly diagnosed systemic lupus erythematosus patients:a steroid-sparing regimen[J].Rheumatology(Oxford, England),2012,51(3):476-481.[34]Reddy V,Cambridge G,Isenberg DA,et al.Internalization of rituximab and the efficiency of B Cell depletion in rheumatoid arthritis and systemic lupus erythematosus[J].Arthritis Rheumatol,2015,67(8):2046-2055.[35]Carter LM,Isenberg DA,Ehrenstein MR.Elevated serum BAFF levels are associated with rising anti-double-stranded DNA antibody levels and disease flare following B cell depletion therapy in systemic lupus erythematosus[J].Arthritis Rheum,2013,65(10):2672-2679.[36]Wallace DJ,Kalunian K,Petri MA,et al.Efficacy and safety of epratuzumab in patients with moderate/severe flaring systemic lupus erythematosus:results from two randomized,double-blind, placebo-controlled,multicentre nstudies(ALLEVIATE)and follow-up[J].Rheumatology(Oxford),2013,52(7):1313-1322.[37]Parker B,Urowitz MB,Gladman DD,et al.Impact of early disease factors on metabolic syndrome in systemic lupus erythematosus:data from an international inception cohort[J].Ann Rheum Dis,2015,74(8):1530-1536.[38]Parker B,Urowitz MB,Gladman DD,et al.Clinical associations of the metabolic syndrome in systemic lupus erythematosus: data from an international inception cohort[J].Ann Rheum Dis,2013,72(8):1308-1314.[39]Hanly JG,Urowitz MB,Su L,et al.Mood Disorders in Systemic Lupus Erythematosus:Results From an International Inception Cohort Study[J].Arthritis Rheumatol,2015,67(7):1837-1847.[40]Little J,Parker B,Lunt M,et al.Glucocorticoid use and factors associated with variability in this use in the Systemic Lupus International Collaborating Clinics Inception Cohort[J].Rheumatology(Oxford),2018,57(4):677-687.[41]Hanly JG,O’Keeffe AG,Su L,et al.The frequency and outcome of lupus nephritis:results from an international inception cohort study[J].Rheumatology(Oxford),2016,55(2):252-262.[42]Hanly JG,Su L,Urowitz MB,et al.A Longitudinal Analysis of Outcomes of Lupus Nephritis in an International Inception Cohort Using a Multistate Model Approach[J].Arthritis Rheumatol,2016,68(8):1932-1944.[43]Bourré-Tessier J,Urowitz MB,Clarke AE,et al.Electrocardiographic findings in systemic lupus erythematosus:data from an international inception cohort[J].Arthritis Care Res (Hoboken),2015,67(1):128-135.[44]Bruce IN,O’Keeffe AG,Farewell V,et al.Factors associated with damage accrual in patients with systemic lupus erythematosus:results from the Systemic Lupus International Collaborating Clinics (SLICC)Inception Cohort[J].Ann Rheum Dis,2015,74(9):1706-1713.[45]Urowitz MB,Gladman DD,Ibanez D,et al.American College of Rheumatology criteria at inception, and accrual over 5 years in the SLICC inception cohort[J].J Rheumatol,2014,41(5):875-880.[46]Hanly JG,Urowitz MB,O’Keeffe AG,et al.Headache in systemic lupus erythematosus:results from a prospective,international inception cohort study[J].Arthritis Rheum,2013,65(11):2887-2897.[47]Aringer M,Smolen JS.Therapeutic blockade of TNF in patients with SLE-promising or crazy[J].Autoimmunity Reviews,2012,11(5):321-325.[48]Aringer M,Smolen JS.Efficacy and safety of TNF-blocker therapy in systemic lupus erythematosus[J].Expert Opinion on Drug Safety,2008,7(4):411-419.[49]Aringer M,Feierl E,Smolen J.Cytokine blockade-a promising therapeutic option in SLE[J].Zeitschriftfür Rheumatologie,2008,67(4):315-317.[50]Aringer M,Smolen JS.The role of tumor necrosis factor-alpha in systemic lupus erythematosus[J].Arthritis Research&Therapy,2008,10(1):202.[51]Aringer M,Steiner G,Graninger WB,et al.Effects of short-term infliximab therapy on autoantibodies in systemic lupus erythematosus[J].Arthritis and Rheumatism,2007,56(1):274-279.[52]Smolen J,Steiner G,Aringer M.Anti-cytokine therapy in systemic lupus erythematosus[J].Lupus,2005,4(3):189-191.[53]Aringer M,Graninger WB,Steiner G,et al.Safety and efficacy of tumor necrosis factor alpha blockade in systemic lupus erythematosus:an open-label study[J].Arthritis and Rheumatism,2004,50(10):3161-3169.[54]Aringer M,Smolen JS.Tumour necrosis factor and other proinflammatory cytokines in systemic lupus erythematosus:a rationale for therapeutic intervention[J].Lupus,2004,13(5):344-347.
相似文献/References:
[1]刘杰荣,罗爱静,黄攀豪,等.基于大数据的单病种住院药品费用合理性筛查实证研究[J].医学信息,2018,31(07):10.[doi:10.3969/j.issn.1006-1959.2018.07.004]
LIU Jie-rong,LUO Ai-Jing,HUANG Pan-hao,et al.An Empirical Study on the Rationality of Cost Screening of Drugs in Hospital with Single Disease Based on Big Data[J].Medical Information,2018,31(23):10.[doi:10.3969/j.issn.1006-1959.2018.07.004]
[2]吴 霞,肖盼盼,谢晓然,等.qRT-PCR法分析复发性SLE患者肠道双歧杆菌、
柔嫩梭菌数量的变化[J].医学信息,2018,31(05):65.[doi:10.3969/j.issn.1006-1959.2018.05.022]
WU Xia,XIAO Pan-pan,XIE Xiao-ran,et al.Analysis of the Changes of Intestinal Bifidobacterium and Clostridium Tenella in Patients with Recurrent SLE by qRT-PCR[J].Medical Information,2018,31(23):65.[doi:10.3969/j.issn.1006-1959.2018.05.022]
[3]白 洁,卓学慧,肖 霄,等.基于“互联网+”背景下医疗健康大数据的应用研究[J].医学信息,2022,35(10):34.[doi:10.3969/j.issn.1006-1959.2022.10.007]
BAI Jie,ZHUO Xue-hui,XIAO Xiao,et al.Application Research of Medical Health Big Data Based on "Internet+"[J].Medical Information,2022,35(23):34.[doi:10.3969/j.issn.1006-1959.2022.10.007]
[4]沈韦辰.互联网大数据时代的医院人事管理创新研究[J].医学信息,2019,32(12):25.[doi:10.3969/j.issn.1006-1959.2019.12.009]
SHEN Wei-chen.Research on Hospital Personnel Management Innovation in the Age of Internet Big Data[J].Medical Information,2019,32(23):25.[doi:10.3969/j.issn.1006-1959.2019.12.009]
[5]张志彬,吴 倩.大数据对医院统计的影响研究[J].医学信息,2019,32(10):6.[doi:10.3969/j.issn.1006-1959.2019.10.003]
ZHANG Zhi-bin,WU Qian.Research on the Impact of Big Data on Hospital Statistics[J].Medical Information,2019,32(23):6.[doi:10.3969/j.issn.1006-1959.2019.10.003]
[6]江启煜,何晓华,刘秀峰,等.中药生物分子信息文献系统的研发与应用[J].医学信息,2019,32(15):10.[doi:10.3969/j.issn.1006-1959.2019.15.004]
JIANG Qi-yu,HE Xiao-hua,LIU Xiu-feng,et al.Development and Application of Traditional Chinese Medicine Biomolecular
Information Document System[J].Medical Information,2019,32(23):10.[doi:10.3969/j.issn.1006-1959.2019.15.004]
[7]屈佳琪,李 洋.核酸传感器与CD72在系统性红斑狼疮中的作用[J].医学信息,2019,32(14):49.[doi:10.3969/j.issn.1006-1959.2019.14.017]
QU Jia-qi,LI Yang.The Role of Nucleic Acid Sensors and CD72 in Systemic Lupus Erythematosus[J].Medical Information,2019,32(23):49.[doi:10.3969/j.issn.1006-1959.2019.14.017]
[8]白巧红.系统性红斑狼疮合并感染的临床特点[J].医学信息,2019,32(23):86.[doi:10.3969/j.issn.1006-1959.2019.23.023]
BAI Qiao-hong.Clinical Features of Systemic Lupus Erythematosus Infection[J].Medical Information,2019,32(23):86.[doi:10.3969/j.issn.1006-1959.2019.23.023]
[9]王 娟,汪 奎,牛彩琴.贝利木单抗治疗系统性红斑狼疮的有效性和安全性的系统评价[J].医学信息,2021,34(21):65.[doi:10.3969/j.issn.1006-1959.2021.21.016]
WANG Juan,WANG Kui,NIU Cai-qin.System Analysis of the Efficacy and Safety of Belimumab in the Treatment of Systemic Lupus Erythematosus[J].Medical Information,2021,34(23):65.[doi:10.3969/j.issn.1006-1959.2021.21.016]
[10]郭万里.基于云服务的区域妇幼保健信息平台的设计[J].医学信息,2020,33(14):10.[doi:10.3969/j.issn.1006-1959.2020.14.004]
GUO Wan-li.Design of Regional Maternity and Child Care Information Platform Based on Cloud Service[J].Medical Information,2020,33(23):10.[doi:10.3969/j.issn.1006-1959.2020.14.004]